Olin and Huntsman, two major US chemical producers, have announced plans to merge in a deal that would combine roughly $12.5B in combined revenues. Both companies are operating at a net loss, making the strategic rationale about cost synergies and scale rather than current profitability.
What happened
Olin and Huntsman, two major US chemical producers, have announced plans to merge in a deal that would combine roughly $12.5B in combined revenues.
The read · Jun 16
With OLN and HUN both running net losses, the question is whether the merger's synergy case is credible enough to re-rate either stock, or whether the deal merely combines two struggling balance sheets.
Wrong if
If deal terms show a heavy stock-for-stock exchange unfavorable to one side, or if regulators signal antitrust scrutiny in chlor-alkali or MDI markets, the spread collapses and both names could re-price lower together.
CoverageSource: C&EN · Published here TUE, JUN 16 · 5:07 PM ET · the only report in this recordHow this is decided →
The chart · OLNTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Olin (OLN, ~$6.8B revenue) and Huntsman (HUN, ~$5.7B revenue) have announced a merger, creating a combined chemicals entity with over $12B in top-line scale. Both companies are currently unprofitable at the net level — OLN at -1.5% net margin and HUN at -4.0% — suggesting the deal is driven by synergy capture, overhead consolidation, and potentially improved pricing power in overlapping chemical markets rather than near-term earnings strength.
The key question is which company's shareholders receive the better deal and whether synergies are real enough to move the needle on profitability. With both stocks carrying negative EPS, the market will scrutinize deal terms, exchange ratios, and management's synergy guidance carefully. Watch for arbitrage spread behavior, any regulatory antitrust review flags, and early analyst reactions to deal structure as the primary near-term price drivers.
The read, in fullWhy it matters
Merger arbitrage and pair setups emerge immediately on deal announcements — the acquiring or premium-receiving entity typically gaps, while the buyer or equity-diluted side lags. Both OLN and HUN carry negative net margins and declining revenues (HUN -5.8% YoY), so synergy credibility is the core valuation driver; until exchange ratios and synergy targets are disclosed, the spread is the trade.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUN 17 on
Next · what would move this
4-8 weeks into deal clarity / financing announcement. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD-24.5%
JUN 17 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
A combined entity with $12.5B in revenues and overlapping chemical manufacturing infrastructure could generate meaningful fixed-cost synergies, potentially flipping both companies' negative net margins into profitability and triggering a re-rating from depressed current multiples.
▼ The case it breaks
Both OLN and HUN are already reporting net losses with declining revenues, meaning the merger combines two operationally challenged businesses — if synergies disappoint or integration costs are high, deal dilution could pressure shares of both companies further.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →